Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

154 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study.
McMeekin DS, Sill MW, Benbrook D, Darcy KM, Stearns-Kurosawa DJ, Eaton L, Yamada SD; Gynecologic Oncology Group. McMeekin DS, et al. Among authors: darcy km. Gynecol Oncol. 2007 May;105(2):508-16. doi: 10.1016/j.ygyno.2007.01.019. Epub 2007 Feb 15. Gynecol Oncol. 2007. PMID: 17306350 Free PMC article. Clinical Trial.
Relationship between ERCC1 polymorphisms, disease progression, and survival in the Gynecologic Oncology Group Phase III Trial of intraperitoneal versus intravenous cisplatin and paclitaxel for stage III epithelial ovarian cancer.
Krivak TC, Darcy KM, Tian C, Armstrong D, Baysal BE, Gallion H, Ambrosone CB, DeLoia JA; Gynecologic Oncology Group Phase III Trial. Krivak TC, et al. Among authors: darcy km. J Clin Oncol. 2008 Jul 20;26(21):3598-606. doi: 10.1200/JCO.2008.16.1323. J Clin Oncol. 2008. PMID: 18640939 Free PMC article. Clinical Trial.
Independent prognostic relevance of microvessel density in advanced epithelial ovarian cancer and associations between CD31, CD105, p53 status, and angiogenic marker expression: A Gynecologic Oncology Group study.
Rubatt JM, Darcy KM, Hutson A, Bean SM, Havrilesky LJ, Grace LA, Berchuck A, Secord AA. Rubatt JM, et al. Among authors: darcy km. Gynecol Oncol. 2009 Mar;112(3):469-74. doi: 10.1016/j.ygyno.2008.11.030. Epub 2009 Jan 9. Gynecol Oncol. 2009. PMID: 19135712 Clinical Trial.
Associations between ERBB2 amplification and progression-free survival and overall survival in advanced stage, suboptimally-resected epithelial ovarian cancers: a Gynecologic Oncology Group Study.
Farley J, Fuchiuji S, Darcy KM, Tian C, Hoskins WJ, McGuire WP, Hanjani P, Warshal D, Greer BE, Belinson J, Birrer MJ. Farley J, et al. Among authors: darcy km. Gynecol Oncol. 2009 Jun;113(3):341-7. doi: 10.1016/j.ygyno.2009.02.009. Epub 2009 Mar 9. Gynecol Oncol. 2009. PMID: 19272639 Free PMC article.
154 results